BioMarin Pharmaceutical Inc. (BMRN) Stock Overview
Explore BioMarin Pharmaceutical Inc.’s financial performance, market position, analyst ratings, and future outlook.
BioMarin Pharmaceutical Inc. (BMRN)
Key Financials
Key Financials
Market Cap
12.8B
P/E Ratio
172.80
EPS (TTM)
$2.08
ROE
0.01%
BMRN Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, BioMarin Pharmaceutical Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of BMRN on the NASDAQ shows an RSI of 55.66, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $57.96 for the NASDAQ listing.
Key metrics behind BioMarin Pharmaceutical Inc.'s NASDAQ-traded stock include a P/E ratio of 172.80 and a market capitalization of 12.8B. Combined with our AI analysis, these give both institutional and retail investors a clear view of BMRN on the NASDAQ.